Quest Laboratories IPO Subscription Status, Rate

Quest Laboratories IPO Subscription Status, Rate

Quest Laboratories IPO Subscription Status: Quest Laboratories IPO is Open on May 15, 2024 and Close on May 17, 2024. Quest Laboratories IPO to Raise 4,449,600 shares (Approx ₹43.16 Cr) via IPO. The Fresh Issue of 4,449,600 Shares (Approx ₹43.16 Cr).

  • The Retail Quota is 35%
  • QIB is 50%
  • NII is 15%.

Quest Laboratories IPO is an SME IPO and Listed on NSE SME. Quest Laboratories IPO Price Band is Fixed at ₹93 to ₹97 Equity Share. Quest Laboratories IPO Lot Size is 1200 Shares.

About Quest Laboratories IPO :

  • Quest Laboratories Limited Is Engaged In The Business Of Manufacturing Of Pharmaceutical Formulations Across A Broad Spectrum, Including Antibiotics, Antimalarials, Antispasmodics, Anti-Inflammatories, Antiemetics, Respiratory Medications, Diabetes Treatments, Antidepressants, And More.
  • Our Company Also Possesses Good Laboratory Practice (GLP) Certificate Issued By Food & Drug Administration, Bhopal, Madhya Pradesh, Indicating Its Commitment To Maintaining High Standards Of Quality And Compliance In Laboratory Operations, Particularly Within The Pharmaceutical Sector.
  • We Maintain Precision, Adhere To Protocols, And Deliver Results In A Timely Manner, All Of Which Are Paramount In Pharmaceutical And Related Industries. Having These Resources And Capabilities In-House Allows Our Company To Support Various Aspects Of Product Development, Quality Control, And Regulatory Compliance. As A Result.

 

Quest Laboratories IPO Subscription Status, Rate bid times

Inv Category Shares Reserved No. of Shares bid for No. of Times (Subscription)
Qualified Buyers (QIBs) 8,31,600 4,75,71,600 57.20
Non Institutional Buyers (NIIs) 6,55,200 12,06,24,000 184.10
Retail Individual Buyers (RIIs) 14,98,800 8,63,70,000 57.63
Anchor Investor 12,36,000 12,36,000 1
Market Maker 2,28,000 2,28,000 1
Total 29,85,600 25,45,65,600 3.59

 

 

Quest Laboratories Subscription Status day-by-day-

Categories 15 May 16 May 17 May
QIB 0.01 0.01 57.20
NII 0.76 2.36 184.10
RII 2.17 6.13 57.63
Total 1.26 3.59 85.26

 

 

 

Quest Laboratories Investor Categories

  • Qualified Institutional Buyers (QIB).
  • Non- Institutional Investors (NII).
  • Retail individual Investors (RII).
  • Employee (EMP).
  • Others (Eligible Shareholders).

Who Is QIB In IPO?

QIB Stands For “Qualified Institutional Buyer” In The Context Of An IPO (Initial Public Offering). QIBs Are A Category Of Institutional Investors Who Are Considered Financially Sophisticated And Meet Certain Regulatory Criteria For Participating In Capital Markets. In The Context Of An IPO, QIBs Play A Significant Role As They Contribute To The Overall Demand For Shares And Help Determine The Success Of The Offering.

Who Is NII In IPO?

NII Stands For “Non-Institutional Investors” In The Context Of An IPO (Initial Public Offering). Non-Institutional Investors Are A Category Of Investors Who Participate In The IPO Alongside Institutional Investors And Retail Investors. NII Typically Includes High Net Worth Individuals (HNIs), Corporate Bodies, Trusts, And Other Entities That Are Not Classified As Institutional Investors But Have The Financial Capacity To Invest Significant Amounts In The IPO.

Who Is RII In IPO?

RII Stands For “Retail Individual Investor” In The Context Of An IPO (Initial Public Offering). Retail Individual Investors Are Individual Investors Who Participate In The IPO Alongside Institutional Investors And Non-Institutional Investors. RII Typically Includes Individual Investors Who Do Not Meet The Criteria To Be Classified As Institutional Investors Or Non-Institutional Investors.

Who Is EMP In IPO?

“EMP” In The Context Of An IPO (Initial Public Offering) Typically Stands For “Employee.” In Some IPOs, A Certain Portion Of The Shares May Be Reserved For Allocation To Employees Of The Company Going Public. These Employees Are Often Referred To As “Employee Shareholders” Or “Employee Participants” (EMP).

Quest Laboratories Review From MoneyMintIdea –

  • May Apply

 

Leave a Comment

Facebook
Twitter
WhatsApp
Telegram
LinkedIn